EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice

Shaohuan Lu, Dongxiao Wang, Caiming Xiong, Jialing Liang, Yang Li, Canhua Liang, Qianxi Chen, Guangyi Meng iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0342188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Shaohuan Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First People's Hospital of Yulin, Yulin, Guangxi, China. Hauptthemen laut MEDLINE: Denosumab, Adverse Drug Reaction Reporting Systems, Data Mining, Bone Density Conservation Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bethune Charitable Foundation 2024 'Radiant China' Pharmaceutical Research Capacity Building Grant, Guangxi Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To detect and quantify adverse drug event (ADE) signals linked to 120 mg denosumab in the real world.

Methods

We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) for reports on 120 mg denosumab, standardized, and categorized these events with Preferred Terms (PT) and System Organ Classes (SOC) from MedDRA version 27.1. Disproportionality analysis was performed using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN).

Results

We identified 10,963 ADE reports for 120 mg of denosumab. Among 10 963 reports, 41.6% of patients were ≥ 65 years old, 37.1% were from the United States, and 17.7% were from Japan; 77.0% were serious. Data mining revealed 294 positive disproportionality signals across 27 SOCs. The highest signal proportions were for neoplasms (15.99%), musculoskeletal disorders (13.27%), infections (11.56%), gastrointestinal disorders (10.88%), and procedural complications (10.20%). The most frequent ADEs were osteonecrosis of the jaw (n = 3,082, 28.11%), death (n = 803, 7.32%), hypocalcemia (n = 799, 7.29%), and fatigue (n = 282, 2.57%). The strongest signals by ROR were bone giant cell tumor (7888.08), bone giant cell tumor malignant (6502.96), osteonecrosis of the jaw (396.57), and bone giant cell tumor benign (312.37). Thirty-two unlisted events were identified, including exostosis of jaw, osteosarcoma, tooth fracture, and bone lesions.

Conclusions

Clinicians should maintain vigilance for both established toxicities and these 32 emerging signals to ensure the safety of patients receiving 120 mg of denosumab for oncological purposes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabAdverse Drug Reaction Reporting SystemsData MiningBone Density Conservation AgentsNeoplasmsHumansFemaleUnited StatesAgedMaleDatabases, FactualMiddle AgedUnited States Food and Drug AdministrationAdultAdolescent

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The First People's Hospital of Yulin, Yulin, Guangxi, China.
  • Department of Pharmacy, Yulin Maternal and Child Health Hospital, Yulin, Guangxi, China.
  • School of Pharmacy, Guangxi Medical University, Nanning, Guangxi, China.
  • Yulin Campus, Guangxi Medical University, Yulin, Guangxi, China.

ORCID-Profile: Guangyi Meng

Förderung

  • Bethune Charitable Foundation 2024 'Radiant China' Pharmaceutical Research Capacity Building Grant
  • Guangxi Science and Technology Major Project

Zitieren

APA

Lu, S., Wang, D., Xiong, C., Liang, J., Li, Y., Liang, C., Chen, Q., & Meng, G. (2026). Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice. PLOS One. https://doi.org/10.1371/journal.pone.0342188

Vancouver

Lu S, Wang D, Xiong C, Liang J, Li Y, Liang C, et al. Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice. PLOS One. 2026. doi:10.1371/journal.pone.0342188

BibTeX
@article{Lu2026,
  author = {Lu, Shaohuan and Wang, Dongxiao and Xiong, Caiming and Liang, Jialing and Li, Yang and Liang, Canhua and Chen, Qianxi and Meng, Guangyi},
  title = {Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0342188}
}
Kostenlos starten →